Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HLC007
MIFTS: 67

Helicobacter Pylori Infection

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Helicobacter Pylori Infection

About this section

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection 57 71
Helicobacter Pylori Infection, Susceptibility to 57 29 6 39
H. Pylori Infection, Susceptibility to 57 13
Helicobacter Pylori Infections 42
H. Pylori Infection 57

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
not determined


Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 600263
MedGen 41 C1838332
UMLS 71 C0850666
Sources

Summaries for Helicobacter Pylori Infection

About this section
MedlinePlus : 42 Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40 percent of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to peptic ulcer disease and atrophic gastritis, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Azithromycin and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and t cells, and related phenotypes are helicobacter pylori infection and Increased viability with MLN4924 (a NAE inhibitor)

OMIM® : 57 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263) (Updated 05-Mar-2021)

Sources

Related Diseases for Helicobacter Pylori Infection

About this section

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 864)
# Related Disease Score Top Affiliating Genes
1 peptic ulcer disease 32.3 TNF NFKB1 IL1RN IL1B IL10 CYP2C19
2 atrophic gastritis 32.0 TNF IL1RN IL1B IL10 CXCL8
3 gastric ulcer 32.0 TNF IL1RN IL1B CYP2C19 CXCL8
4 purpura 31.8 TNF IL1B IL10
5 peptic esophagitis 31.7 TNF IL1B CYP2C19 CXCL8
6 esophagitis 31.7 TNF IL1B IL10 CYP2C19 CXCL8
7 gastritis 31.6 TNF NOD1 IL1RN IL1B IL10 CYP2C19
8 gastroesophageal reflux 31.6 TNF IL1RN IL1B EGFR CYP2C19 CXCL8
9 duodenal ulcer 31.6 TNF NOD1 IL1RN IL1B IL10 CYP2C19
10 fatty liver disease 31.4 TNF IL1B CXCL8 CASP3
11 autoimmune gastritis 31.4 TNF IL1B IL10
12 hepatitis a 31.3 TNF IL1B IL10
13 diarrhea 31.3 TNF IL1B IL10 EGFR CXCL8
14 celiac disease 1 31.3 TNF IL1B IL10 CXCL8
15 pustulosis of palm and sole 31.2 TNF IL1RN CXCL8
16 liver disease 31.2 TNF NFKB1 IL1B CXCL8 CASP3
17 thyroiditis 31.2 TNF IL1B IL10
18 bacterial infectious disease 31.2 TNF NOD1 IL1RN IL1B IL10 CXCL8
19 chlamydia pneumonia 31.2 TNF IL1B IL10 CXCL8
20 disease by infectious agent 31.1 TNF IL1RN IL1B IL10 IFNGR1
21 irritable bowel syndrome 31.1 TNF IL1B IL10 CXCL8
22 chronic spontaneous urticaria 31.1 TNF CXCL8 CCL5
23 end stage renal disease 31.1 TNF IL1RN IL1B IL10
24 chlamydia 31.0 TNF NOD1 IL1B IL10 CXCL8
25 stomatitis 31.0 TNF IL1B IL10 CXCL8
26 type 1 diabetes mellitus 31.0 TNF IL1RN IL1B IL10 CXCL8
27 gastroenteritis 31.0 TNF IL1RN IL1B IL10 CXCL8
28 typhoid fever 30.9 TNF IL1B IFNGR1
29 food allergy 30.9 TNF IL10 CXCL8
30 exanthem 30.9 TNF IL1B IL10 EGFR CXCL8
31 alopecia areata 30.9 TNF IL1RN IL1B IL10
32 gastric cancer 30.9 PTPN11 PAK1 MET JUN IL1RN IL1B
33 lichen planus 30.8 TNF IL1B IL10 CXCL8
34 lipoprotein quantitative trait locus 30.8 TNF IL1RN IL1B IL10 CXCL8 CASP3
35 proteasome-associated autoinflammatory syndrome 1 30.8 TNF IL1RN IL1B IL10 CXCL8 CCL5
36 periodontitis 30.8 TNF IL1RN IL1B IL10 CXCL8
37 brucellosis 30.7 TNF IL1RN IL10 CXCL8
38 ulcerative colitis 30.7 TNF IL1RN IL1B IL10 CXCL8
39 crohn's colitis 30.7 TNF IL1B CXCL8
40 iridocyclitis 30.7 TNF IL1B IL10
41 pharyngitis 30.7 TNF IL1B CXCL8
42 aphthous stomatitis 30.7 TNF IL1RN IL1B IL10 CXCL8
43 otitis media 30.6 TNF IL1B IL10 CXCL8
44 uveitis 30.6 TNF IL1B IL10 CXCL8
45 bronchitis 30.6 TNF IL1B IL10 CXCL8 CCL5
46 dermatitis, atopic 30.6 TNF IL1B IL10 CXCL8 CCL5
47 mycobacterium fortuitum 30.6 IFNGR1 CXCL8
48 alcoholic liver cirrhosis 30.5 TNF IL1B IL10 CXCL8
49 sclerosing cholangitis 30.5 TNF IL10 CXCL8
50 acne 30.5 TNF IL1RN IL1B CXCL8

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:



Diseases related to Helicobacter Pylori Infection
Sources

Symptoms & Phenotypes for Helicobacter Pylori Infection

About this section

Human phenotypes related to Helicobacter Pylori Infection:

31
# Description HPO Frequency HPO Source Accession
1 helicobacter pylori infection 31 HP:0005202

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
G I:
helicobacter pylori infection susceptibility

Clinical features from OMIM®:

600263 (Updated 05-Mar-2021)

UMLS symptoms related to Helicobacter Pylori Infection:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, dyspepsia, icterus, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.85 CASP3 CHUK IL10 IL1B NFKB1 NFKBIA
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.85 JUN NFKB1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.66 CASP3 CHUK CXCL8 IL10 IL1B JUN
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.66 CASP3 CHUK CXCL8 IL10 IL1B JUN
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.66 JUN NFKB1
6 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.56 CASP3 CXCL8 PTPN11 TNF
7 Increased viability with paclitaxel GR00179-A-1 8.65 CASP3

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
2 hematopoietic system MP:0005397 10.44 ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
3 immune system MP:0005387 10.44 ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
4 cardiovascular system MP:0005385 10.41 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
5 homeostasis/metabolism MP:0005376 10.4 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
6 growth/size/body region MP:0005378 10.36 ADAM10 CASP3 CHUK EGFR IL10 IL1B
7 endocrine/exocrine gland MP:0005379 10.34 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
8 craniofacial MP:0005382 10.32 ADAM10 CASP3 CHUK EGFR IL10 IL1B
9 integument MP:0010771 10.31 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
10 mortality/aging MP:0010768 10.28 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
11 digestive/alimentary MP:0005381 10.27 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
12 embryo MP:0005380 10.22 ADAM10 CHUK EGFR IFNGR1 IL10 JUN
13 nervous system MP:0003631 10.13 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
14 liver/biliary system MP:0005370 10.11 CHUK EGFR IFNGR1 IL10 JUN MET
15 limbs/digits/tail MP:0005371 10.02 CHUK EGFR IL10 JUN MET PTPN11
16 muscle MP:0005369 10.01 CASP3 EGFR IL10 MET NFKB1 PAK1
17 neoplasm MP:0002006 9.97 CHUK EGFR IFNGR1 IL10 IL1B MET
18 normal MP:0002873 9.81 ADAM10 EGFR IL10 JUN MET NFKB1
19 no phenotypic analysis MP:0003012 9.8 CASP3 EGFR IL10 JUN MET PTPN11
20 respiratory system MP:0005388 9.65 CASP3 CHUK EGFR IL10 JUN MET
21 skeleton MP:0005390 9.44 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
Sources

Drugs & Therapeutics for Helicobacter Pylori Infection

About this section

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 55185 447043
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
carbamide peroxide Approved Phase 4 124-43-6
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
6
Loperamide Approved Phase 4 53179-11-6 3955
7
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
8
Titanium dioxide Approved Phase 4 13463-67-7
9
Coal tar Approved Phase 4 8007-45-2
10
Clarithromycin Approved Phase 4 81103-11-9 84029
11
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
12
Sodium citrate Approved, Investigational Phase 4 68-04-2
13
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
14
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
15
Trimebutine Approved Phase 4 39133-31-8
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
19
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
20
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Lactoferrin Investigational Phase 4 151186-19-5
23
Sulforaphane Investigational Phase 4 142825-10-3, 4478-93-7 5350
24
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
25
Meclocycline Investigational Phase 4 2013-58-3 5480760
26 Antitubercular Agents Phase 4
27 N-monoacetylcystine Phase 4
28 Bile Acids and Salts Phase 4
29 Antioxidants Phase 4
30 Antiviral Agents Phase 4
31 Antidotes Phase 4
32 Ubiquinone Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
35 Antidiarrheals Phase 4
36 Pharmaceutical Solutions Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Cytochrome P-450 CYP3A Inhibitors Phase 4
39 Antimalarials Phase 4
40 Respiratory System Agents Phase 4
41 Citrate Phase 4
42 Expectorants Phase 4
43 penicillins Phase 4
44 Fluoroquinolones Phase 4
45 Protective Agents Phase 4
46 Sulforafan Phase 4
47 Bifidobacterium Phase 4
48 Monoamine Oxidase Inhibitors Phase 4
49 Anti-Infective Agents, Local Phase 4
50 Liver Extracts Phase 4

Interventional clinical trials:

(show top 50) (show all 290)
# Name Status NCT ID Phase Drugs
1 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
2 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
3 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
4 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
5 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
6 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
7 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
8 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Unknown status NCT03299725 Phase 4 colloidal bismuth sub-citrate
9 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03571230 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone);one proton pump inhibitor(PPI);Colloidal Bismuth Pectin;two antibiotics for failed eradication(tetracyclin,furazolidone)
10 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
11 The Efficacy of Probiotic Supplementation in the Reduction of Adverse Effects and Dysbiosis of Helicobacter Pylori Eradication Therapy - A Double Blind, Multi-center Randomized, Placebo Controlled Trial Unknown status NCT03722433 Phase 4 Vigiis 101-LAB and sequential therapy;Placebo and sequential therapy
12 Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial Unknown status NCT03208426 Phase 4 Esomeprazole (S14);Esomeprazole (BQ10);Amoxicillin (ST14);Clarithromycin (ST14);Metronidazole (ST14);dibismuth trioxide 120mg (BQ10);Metronidazole (BQ10);tetracycline (BQ10)
13 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
14 Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy Unknown status NCT02894268 Phase 4 Doxycycline;Furazolidone;Esomeprazole;Colloidal Bismuth Subcitrate;Sensitivity antibiotics
15 THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY Unknown status NCT03757650 Phase 4 Bismuth Subsalicylate
16 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
17 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
18 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
19 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
20 Analysis of the Impact of Helicobacter Pylori Infection and Eradication on Salivary Microbiome in Adults by 16S Pyrosequencing Unknown status NCT03730766 Phase 4 Esomeprazole;Amoxicillin;Bismuth Potassium Citrate
21 Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: an Open Randomized Pilot Study Unknown status NCT03658733 Phase 4 esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days);rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
22 Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection Unknown status NCT01725906 Phase 4 empirical therapy;Genotypic resistance guided therapy
23 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT01537055 Phase 4 levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
24 Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Unknown status NCT02934048 Phase 4
25 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
26 Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01607918 Phase 4 D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
27 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
28 Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea; Open-label, Randomized Controlled Trial Completed NCT03665428 Phase 4 PAMB treatment (modified quadruple therapy);PBMT treatment (bismuth-containing quadruple therapy)
29 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
30 Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection Completed NCT01085786 Phase 4 14-day sequential treatment;14-day hybrid treatment
31 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
32 Comparing the Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinidazole on Rate of Eradication of Helicobacter Pylori Infected Patients on Syrian Population Completed NCT04348786 Phase 4 Doxycycline;Levofloxacin 500mg
33 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
34 An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
35 Randomized Clinical Trial: the Comparison of 15-day Sequential and 10-day Sequential Therapy to PPI-based Triple Therapy for Helicobacter Pylori Infection in Korea Completed NCT01887249 Phase 4 Clarithromycin;metronidazole;esomeprazole
36 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
37 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
38 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
39 Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT01742429 Phase 4 Proton pump inhibitor;Bismuth subsalicylate;Metronidazole;Tetracycline;Amoxicillin;Levofloxacin
40 A Randomized Clinical Trial of Clarithromycin/Bismuth Containing Quadruple Therapy for Helicobacter Pylori First-line Treatment Completed NCT02732249 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole
41 Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials Completed NCT01967329 Phase 4 Standard Triple;Sequential;Quadruple
42 Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait Completed NCT04617613 Phase 4 Omeprazole, Amoxicillin, Metronidazole and Clarithromycin;Omeprazole, Amoxicillin and Clarithromycin
43 Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial Completed NCT03557437 Phase 4 Esomeprazole;Amoxicillin, Metronidazole;Bismuth Potassium Citrate
44 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
45 Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan Completed NCT01769365 Phase 4 7-day quadruple therapy;10-day sequential therapy;7-day standard triple therapy
46 Efficacy of High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment：a Randomized Clinical Trial Completed NCT03405584 Phase 4 Esomeprazole;Amoxicillin;Bismuth Potassium Citrate
47 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02490839 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
48 Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori Completed NCT01573975 Phase 4 5RA-5RCM;5RA-5RCT;10RCA
49 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03832465 Phase 4 Levofloxacin film-coated tablet;Levofloxacin intravenous solution
50 Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability Completed NCT04132479 Phase 4 Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg;Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg

Search NIH Clinical Center for Helicobacter Pylori Infection

Sources

Genetic Tests for Helicobacter Pylori Infection

About this section

Genetic tests related to Helicobacter Pylori Infection:

# Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 29 IFNGR1
Sources

Anatomical Context for Helicobacter Pylori Infection

About this section

MalaCards organs/tissues related to Helicobacter Pylori Infection:

40
Liver, Heart, T Cells, Neutrophil, Whole Blood, Kidney, Thyroid
Sources

Publications for Helicobacter Pylori Infection

About this section

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 12719)
# Title Authors PMID Year
1
Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. 61 57 6
12516030 2003
2
Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. 61 57
15310903 2004
3
Transmission of Helicobacter pylori infection. 61 57
7672655 1995
4
Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection. 61 57
7878011 1995
5
Helicobacter pylori infection: genetic and environmental influences. A study of twins. 61 57
8185146 1994
6
Seroprevalence of helicobacter pylori infection in couples. 57 61
2037687 1991
7
Association between Helicobacter pylori infection and irritable bowel syndrome: A systematic review and meta-analysis. 42 61
33327230 2020
8
A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. 57
22387998 2012
9
A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. 6
19488747 2009
10
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 57
18488030 2008
11
Helicobacter exploits integrin for type IV secretion and kinase activation. 57
17943123 2007
12
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. 6
16690980 2006
13
Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. 57
15051885 2004
14
Treatment of Helicobacter gastritis with IL-4 requires somatostatin. 57
14555768 2003
15
Protective immunity against Helicobacter is characterized by a unique transcriptional signature. 57
14528007 2003
16
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. 57
12598897 2003
17
Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. 57
12730721 2003
18
Helicobacter pylori and gastrointestinal tract adenocarcinomas. 57
11902583 2002
19
Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. 57
11535550 2001
20
The complete genome sequence of the gastric pathogen Helicobacter pylori. 57
9252185 1997
21
Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. 57
8040281 1994
22
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. 57
8163943 1994
23
Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. 57
8018146 1993
24
Purification and characterization of the vacuolating toxin from Helicobacter pylori. 57
1587837 1992
25
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. 57
6134060 1983
26
Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction. 42
33144087 2021
27
The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study. 42
33157939 2020
28
Alzheimer's disease and gastrointestinal microbiota; impact of Helicobacter pylori infection involvement. 61
32125206 2021
29
Association between glycemic index and Helicobacter pylori infection risk among adults: A case-control study. 61
33348108 2021
30
Routine panendoscopy in oral squamous cell cancer patients: mandatory or facultative? 61
32607829 2021
31
Diet and cancer of the esophagus and stomach. 61
33315794 2021
32
The impact of ICOS+ regulatory T cells and Helicobacter pylori infection on the prognosis of patients with gastric and colorectal cancer: potential prognostic benefit of pre-operative eradication therapy. 61
32803278 2021
33
"Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france". 61
33586832 2021
34
Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa. 61
33596339 2021
35
Correction to: Sperm parameters and anti-Müllerian hormone remain stable with Helicobacter pylori infection: a cross-sectional study. 61
33546630 2021
36
Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. 61
33113240 2021
37
Helicobacter pylori infection worsens impaired glucose regulation in high-fat diet mice in association with an altered gut microbiome and metabolome. 61
33576881 2021
38
A retrospective study assessing the acceleration effect of type I Helicobacter pylori infection on the progress of atrophic gastritis. 61
33603125 2021
39
The novel ZEB1-upregulated protein PRTG induced by Helicobacter pylori infection promotes gastric carcinogenesis through the cGMP/PKG signaling pathway. 61
33542225 2021
40
GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. 61
33608531 2021
41
Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study. 61
32804837 2021
42
Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years. 61
33073418 2021
43
Stool Antigen Testing, a Reliable Noninvasive Method of Assessment of Helicobacter pylori Infection Among Patients with Gastro-duodenal Disorders in Cameroon. 61
32350723 2021
44
High Body Mass Index Is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection. 61
33536385 2021
45
The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. 61
32960107 2021
46
Bioinformatic identification of key pathways, hub genes, and microbiota for therapeutic intervention in Helicobacter pylori infection. 61
32710499 2021
47
Sustained Helicobacter pylori infection accelerates gastric dysplasia in a mouse model. 61
33310760 2021
48
Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding. 61
32289532 2021
49
Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration. 61
32272245 2021
50
Upper Gastrointestinal Bleeding. 61
33213769 2021
Sources

Variations for Helicobacter Pylori Infection

About this section

ClinVar genetic disease variations for Helicobacter Pylori Infection:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IFNGR1 IFNGR1, -56C-T SNV risk factor 17953
2 IFNGR1 NM_000416.3(IFNGR1):c.974C>T (p.Pro325Leu) SNV Uncertain significance 992563 6:137519664-137519664 6:137198527-137198527
Sources

Expression for Helicobacter Pylori Infection

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Helicobacter Pylori Infection patients vs. healthy controls: 35 (show top 50) (show all 94)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FDCSP follicular dendritic cell secreted protein Gastrointestinal Tract,Stomach + 9.19 0.000
2 DMBT1 deleted in malignant brain tumors 1 Gastrointestinal Tract,Stomach + 7.69 0.000
3 REG3G regenerating family member 3 gamma Gastrointestinal Tract,Stomach + 6.56 0.000
4 CR2 complement C3d receptor 2 Gastrointestinal Tract,Stomach + 6.52 0.000
5 OLFM4 olfactomedin 4 Gastrointestinal Tract,Stomach + 6.34 0.001
6 CXCL13 C-X-C motif chemokine ligand 13 Gastrointestinal Tract,Stomach + 6.24 0.000
7 REG3A regenerating family member 3 alpha Gastrointestinal Tract,Stomach + 6.15 0.000
8 CD19 CD19 molecule Gastrointestinal Tract,Stomach + 5.25 0.000
9 FCRL3 Fc receptor like 3 Gastrointestinal Tract,Stomach + 5.18 0.000
10 CXCR5 C-X-C motif chemokine receptor 5 Gastrointestinal Tract,Stomach + 5.12 0.000
11 SAA2 serum amyloid A2 Gastrointestinal Tract,Stomach + 4.81 0.000
12 MS4A1 membrane spanning 4-domains A1 Gastrointestinal Tract,Stomach + 4.76 0.000
13 CCL20 C-C motif chemokine ligand 20 Gastrointestinal Tract,Stomach + 4.64 0.000
14 ABCA12 ATP binding cassette subfamily A member 12 Gastrointestinal Tract,Stomach + 4.60 0.000
15 SAA1 serum amyloid A1 Gastrointestinal Tract,Stomach + 4.59 0.000
16 NLRP7 NLR family pyrin domain containing 7 Gastrointestinal Tract,Stomach + 4.56 0.000
17 CCL19 C-C motif chemokine ligand 19 Gastrointestinal Tract,Stomach + 4.52 0.000
18 VNN1 vanin 1 Gastrointestinal Tract,Stomach + 4.51 0.000
19 BPIFB1 BPI fold containing family B member 1 Gastrointestinal Tract,Stomach + 4.48 0.000
20 AFAP1-AS1 AFAP1 antisense RNA 1 Gastrointestinal Tract,Stomach + 4.47 0.000
21 CCR7 C-C motif chemokine receptor 7 Gastrointestinal Tract,Stomach + 4.38 0.000
22 CXCL1 C-X-C motif chemokine ligand 1 Gastrointestinal Tract,Stomach + 4.33 0.000
23 CHI3L1 chitinase 3 like 1 Gastrointestinal Tract,Stomach + 4.30 0.000
24 DEFB4A defensin beta 4A Gastrointestinal Tract,Stomach + 4.25 0.000
25 LAIR2 leukocyte associated immunoglobulin like receptor 2 Gastrointestinal Tract,Stomach + 4.22 0.000
26 TCL1A TCL1 family AKT coactivator A Gastrointestinal Tract,Stomach + 4.16 0.000
27 SELL selectin L Gastrointestinal Tract,Stomach + 4.14 0.000
28 S100A8 S100 calcium binding protein A8 Gastrointestinal Tract,Stomach + 4.09 0.000
29 FCRL5 Fc receptor like 5 Gastrointestinal Tract,Stomach + 3.95 0.000
30 TLR10 toll like receptor 10 Gastrointestinal Tract,Stomach + 3.95 0.000
31 C3 complement C3 Gastrointestinal Tract,Stomach + 3.95 0.000
32 LCN2 lipocalin 2 Gastrointestinal Tract,Stomach + 3.92 0.000
33 MMP7 matrix metallopeptidase 7 Gastrointestinal Tract,Stomach + 3.88 0.000
34 CD28 CD28 molecule Gastrointestinal Tract,Stomach + 3.80 0.000
35 BLK BLK proto-oncogene, Src family tyrosine kinase Gastrointestinal Tract,Stomach + 3.80 0.000
36 CD22 CD22 molecule Gastrointestinal Tract,Stomach + 3.80 0.000
37 FCRL2 Fc receptor like 2 Gastrointestinal Tract,Stomach + 3.78 0.000
38 CXCL8 C-X-C motif chemokine ligand 8 Gastrointestinal Tract,Stomach + 3.77 0.000
39 FCRL4 Fc receptor like 4 Gastrointestinal Tract,Stomach + 3.72 0.000
40 CXCL2 C-X-C motif chemokine ligand 2 Gastrointestinal Tract,Stomach + 3.69 0.000
41 CD180 CD180 molecule Gastrointestinal Tract,Stomach + 3.68 0.000
42 PLA2G7 phospholipase A2 group VII Gastrointestinal Tract,Stomach + 3.66 0.000
43 FCAMR Fc fragment of IgA and IgM receptor Gastrointestinal Tract,Stomach + 3.65 0.000
44 AQP9 aquaporin 9 Gastrointestinal Tract,Stomach + 3.64 0.000
45 FCRLA Fc receptor like A Gastrointestinal Tract,Stomach + 3.63 0.000
46 AIM2 absent in melanoma 2 Gastrointestinal Tract,Stomach + 3.63 0.000
47 LTF lactotransferrin Gastrointestinal Tract,Stomach + 3.63 0.000
48 KRT6B keratin 6B Gastrointestinal Tract,Stomach + 3.60 0.000
49 C6 complement C6 Gastrointestinal Tract,Stomach - 3.60 0.000
50 NEURL3 neuralized E3 ubiquitin protein ligase 3 Gastrointestinal Tract,Stomach + 3.59 0.000
Search GEO for disease gene expression data for Helicobacter Pylori Infection.
Sources

Pathways for Helicobacter Pylori Infection

About this section

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.33 TNF PTPN11 PAK1 NFKBIA NFKB1 MET
2
Innate Immune System 65
Show member pathways
 14.07 TNF PTPN11 PAK1 NOD1 NFKBIA NFKB1
3
ERK Signaling 63
Show member pathways
 14.01 TNF PAK1 NFKBIA NFKB1 MET JUN
4
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 13.98 TNF PAK1 NFKBIA NFKB1 MET JUN
5
PEDF Induced Signaling 63
Show member pathways
 13.85 TNF NFKBIA NFKB1 MET JUN IL1RN
6
TGF-Beta Pathway 63
Show member pathways
 13.74 TNF PTPN11 PAK1 NFKBIA NFKB1 MET
7
Developmental Biology 65
Show member pathways
 13.63 TNF PTPN11 PAK1 NFKB1 MET JUN
8
Akt Signaling 63
Show member pathways
 13.62 TNF PAK1 NFKB1 MET IL1B IL10
9
Integrin Pathway 63
Show member pathways
 13.55 PAK1 NFKB1 JUN EGFR CXCL8 CXCL1
10
IL-2 Pathway 63
Show member pathways
 13.41 TNF PAK1 NFKBIA NFKB1 JUN IL1B
11
Cytokine Signaling in Immune system 65
Show member pathways
 13.35 TNF PTPN11 NOD1 NFKB1 MET IL1RN
12
TNFR1 Pathway 63
Show member pathways
 13.28 TNF PAK1 NFKBIA NFKB1 JUN EGFR
13
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.26 TNF NFKBIA NFKB1 JUN IL1B IL10
14
p70S6K Signaling 63
Show member pathways
 13.18 PAK1 NFKB1 MET JUN EGFR CHUK
15
fMLP Pathway 63
Show member pathways
 13.17 PAK1 NFKBIA NFKB1 MET JUN CHUK
16
PI3K-Akt signaling pathway 36
Show member pathways
 13.13 TNF NFKB1 MET EGFR CHUK CASP3
17
CCR5 Pathway in Macrophages 63
Show member pathways
 13.1 PAK1 NFKBIA NFKB1 JUN CXCL8 CXCL1
18
Pathways in cancer 36
13.08 NFKBIA NFKB1 MET JUN IFNGR1 EGFR
19
Measles 36
Show member pathways
 13.07 TNF NFKBIA NFKB1 JUN IL1B IFNGR1
20
Endometrial cancer 36
Show member pathways
 13.06 PTPN11 NFKBIA NFKB1 JUN EGFR CHUK
21
Herpes simplex virus 1 infection 36
13.04 TNF PTPN11 NFKBIA NFKB1 IL1B IFNGR1
22
MAPK signaling pathway 36 1
13 TNF PAK1 NFKB1 MET JUN IL1B
23
Allograft rejection 36 1
Show member pathways
 12.97 TNF IL1B IL10 CXCL8 CASP3
24
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.95 TNF PTPN11 NFKBIA NFKB1 JUN CHUK
25
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.95 TNF NOD1 NFKBIA NFKB1 JUN IL1RN
26
Development HGF signaling pathway 23
Show member pathways
 12.93 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
27
NF-KappaB Family Pathway 63
Show member pathways
 12.92 TNF NFKBIA NFKB1 MET IL1B EGFR
28
4-1BB Pathway 63
Show member pathways
 12.92 TNF NFKBIA NFKB1 JUN IL1B IFNGR1
29
Ras signaling pathway 36
Show member pathways
 12.91 PTPN11 PAK1 NFKB1 MET EGFR CHUK
30
Salmonella infection (KEGG) 36
Show member pathways
 12.91 TNF PTPN11 PAK1 NOD1 NFKBIA NFKB1
31
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.9 PTPN11 NFKBIA NFKB1 MET EGFR CHUK
32
Apoptosis Modulation and Signaling 1
Show member pathways
 12.88 TNF NFKBIA NFKB1 JUN CHUK CASP3
33
Immune response NFAT in immune response 23
Show member pathways
 12.87 TNF PAK1 NFKBIA NFKB1 JUN IL10
34
nNOS Signaling in Skeletal Muscle 63
Show member pathways
 12.86 TNF PAK1 NFKB1 JUN EGFR CASP3
35
Th17 cell differentiation 36
Show member pathways
 12.85 TNF NFKBIA NFKB1 JUN IL1B IL10
36
TRAF Pathway 63
Show member pathways
 12.84 TNF PAK1 NFKBIA NFKB1 JUN IL1B
37
ErbB signaling pathway 36 1
Show member pathways
 12.81 PTPN11 PAK1 NFKB1 MET JUN EGFR
38
NF-kappaB Signaling 4
12.81 TNF NOD1 NFKBIA NFKB1 IL1RN IL1B
39
Immune response IL-23 signaling pathway 23
Show member pathways
 12.8 TNF PTPN11 PAK1 NFKBIA NFKB1 IL1B
40
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.78 TNF PTPN11 NFKBIA NFKB1 JUN CHUK
41
Human cytomegalovirus infection 36
Show member pathways
 12.77 TNF PAK1 NFKBIA NFKB1 JUN IL1B
42
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.75 NOD1 NFKBIA NFKB1 IL1B CHUK CCL5
43
Prolactin Signaling Pathway 1 36
Show member pathways
 12.74 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1RN
44
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.72 TNF PTPN11 PAK1 JUN IFNGR1 CASP3
45
Apoptosis Pathway 70
Show member pathways
 12.71 NFKBIA NFKB1 MET JUN IL1B EGFR
46
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.7 TNF NFKBIA NFKB1 CXCL8 CHUK
47
T cell receptor signaling pathway 36
Show member pathways
 12.69 TNF PTPN11 PAK1 NFKBIA NFKB1 JUN
48
VEGF Signaling 66
Show member pathways
 12.66 PAK1 NFKB1 JUN EGFR CASP3
49
RANK Signaling in Osteoclasts 63
Show member pathways
 12.64 PAK1 NFKBIA NFKB1 JUN IL10 CHUK
50
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.62 PTPN11 PAK1 NFKBIA NFKB1 JUN CHUK
Sources

GO Terms for Helicobacter Pylori Infection

About this section

Cellular components related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF NFKB1 MET IL1RN IL1B IL10
2 I-kappaB/NF-kappaB complex GO:0033256 8.62 NFKBIA NFKB1

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF NFKBIA NFKB1 MET JUN IL10
2 signal transduction GO:0007165 10.21 PAK1 NOD1 NFKB1 MET IL1RN IL1B
3 apoptotic process GO:0006915 10.17 PAK1 NOD1 NFKBIA NFKB1 IL1B CASP3
4 protein phosphorylation GO:0006468 10.16 PAK1 MET EGFR CHUK CCL5 ADAM10
5 negative regulation of apoptotic process GO:0043066 10.12 NFKBIA NFKB1 IL10 EGFR CASP3 ADAM10
6 intracellular signal transduction GO:0035556 10.11 NOD1 EGFR CXCL8 CXCL1 CASP3
7 positive regulation of transcription, DNA-templated GO:0045893 10.08 TNF NFKBIA NFKB1 JUN IL1B IL10
8 positive regulation of cell migration GO:0030335 10.03 PAK1 IL1B EGFR CCL5 ADAM10
9 positive regulation of protein phosphorylation GO:0001934 10.01 TNF PAK1 IL1B EGFR
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 TNF PTPN11 NOD1 EGFR CCL5
11 positive regulation of protein kinase B signaling GO:0051897 10 TNF PTPN11 MET EGFR
12 Fc-epsilon receptor signaling pathway GO:0038095 9.99 PAK1 NFKB1 JUN CHUK
13 defense response GO:0006952 9.99 TNF NOD1 CXCL8 CXCL1
14 MAPK cascade GO:0000165 9.97 TNF PAK1 MET IL1B EGFR CCL5
15 activation of MAPK activity GO:0000187 9.95 TNF PTPN11 NOD1 IL1B
16 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF NOD1 NFKB1 IL1B CHUK
17 response to virus GO:0009615 9.94 TNF IFNGR1 CHUK CCL5
18 positive regulation of inflammatory response GO:0050729 9.92 TNF NFKBIA IL1B EGFR
19 positive regulation of interleukin-6 production GO:0032755 9.92 TNF PTPN11 NOD1 IL1B
20 immune response GO:0006955 9.92 TNF IL1RN IL1B IL10 CXCL8 CXCL1
21 cellular response to tumor necrosis factor GO:0071356 9.91 NFKBIA NFKB1 CXCL8 CHUK CCL5
22 neutrophil chemotaxis GO:0030593 9.9 CXCL8 CXCL1 CCL5
23 regulation of insulin secretion GO:0050796 9.9 TNF IL1B CCL5
24 chemokine-mediated signaling pathway GO:0070098 9.9 CXCL8 CXCL1 CCL5
25 cellular response to mechanical stimulus GO:0071260 9.9 PTPN11 NFKB1 IL1B EGFR
26 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.89 TNF NFKBIA CHUK
27 positive regulation of interleukin-8 production GO:0032757 9.88 TNF NOD1 IL1B
28 cellular response to organic cyclic compound GO:0071407 9.88 TNF IL1B CCL5 CASP3
29 response to lipopolysaccharide GO:0032496 9.88 NFKBIA JUN IL1B IL10 CHUK CASP3
30 positive regulation of neuron apoptotic process GO:0043525 9.87 TNF JUN CASP3
31 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF NOD1 IL1B EGFR
32 response to glucocorticoid GO:0051384 9.86 TNF IL1RN IL10 CASP3
33 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.85 TNF JUN IL10
34 protein kinase B signaling GO:0043491 9.85 TNF IL1B CCL5
35 cellular response to reactive oxygen species GO:0034614 9.85 JUN EGFR CHUK
36 cellular response to lipopolysaccharide GO:0071222 9.85 TNF NFKB1 IL1B IL10 CXCL8 CXCL1
37 cellular response to cadmium ion GO:0071276 9.84 JUN EGFR CHUK
38 negative regulation of mitotic cell cycle GO:0045930 9.84 TNF IL10 EGFR
39 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 TNF JUN EGFR CCL5
40 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.83 TNF PAK1 JUN IL10
41 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL10 CCL5
42 positive regulation of amyloid-beta formation GO:1902004 9.78 TNF IFNGR1 CASP3
43 astrocyte activation GO:0048143 9.77 TNF IFNGR1 EGFR
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.76 TNF IL1B IL10
45 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TNF NFKBIA IL1B CCL5
46 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNGR1
47 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.73 IL1RN IL10
48 response to molecule of bacterial origin GO:0002237 9.73 IL10 CXCL8
49 regulation of establishment of endothelial barrier GO:1903140 9.73 TNF IL1B
50 interleukin-1-mediated signaling pathway GO:0070498 9.73 NOD1 NFKBIA NFKB1 IL1RN IL1B CHUK

Molecular functions related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 9.65 NOD1 JUN EGFR CHUK CASP3
2 identical protein binding GO:0042802 9.61 TNF PAK1 NOD1 NFKBIA NFKB1 MET
3 chemokine activity GO:0008009 9.33 CXCL8 CXCL1 CCL5
4 cytokine activity GO:0005125 9.17 TNF IL1RN IL1B IL10 CXCL8 CXCL1
Sources

Sources for Helicobacter Pylori Infection

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....